Abstract
Six children with anti-NMDAR encephalitis were followed-up for 6 to 24 months. They presented with seizures, neuropsychiatric symptoms and movement disorder, particularly orofacial dyskinesia and choreoathetosis. Immunosuppressive therapy resulted in varying degrees of improvement; none relapsed. Expressive aphasia was the last symptom to regress.
Similar content being viewed by others
References
Turner D, Ruemmele FM, Orlanski–Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care–An Evidence–based Guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91.
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN Revised Porto Criteria for the diagnosis of Inflammatory Bowel Disease in Children and Adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.
Quail MA, Russell RK, Van Limbergen JE, Rogers P, Drummon HE, Wilson DC, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:756–9.
Diamanti A, Panetta F, Basso MS, Forgione A, Colistro F, Bracci F, et al. Diagnostic work up of inflammatory bowel disease in children: The role of calprotectin assay. Inflamm Bowel Dis. 2010;16:1926–30.
Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta–analysis. BMJ. 2010;341:c3369.
Kelsen J, Baldassano RN. Inflammatory bowel disease: The difference between children and adults. Inflamm Bowel Dis. 2008;14:S9–11.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sridhar, M., Kesavelu, D. Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. Indian Pediatr 56, 247–250 (2019). https://doi.org/10.1007/s13312-019-1509-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-019-1509-3